共 126 条
[1]
Kravitz RL(2004)Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages Milbank Q 82 661-87
[2]
Duan N(2010)Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal Trials. 11 85-12
[3]
Braslow J(2007)Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification JAMA 298 1209-7
[4]
Kent DM(2003)Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke 34 464-22
[5]
Rothwell PM(2002)Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned Circulation 105 917-9
[6]
Ioannidis JP(2006)Moderators of treatment outcomes: clinical, research, and policy importance JAMA 296 1286-30
[7]
Altman DG(2002)Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems Stat Med 21 2917-86
[8]
Hayward RA(2005)Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation Lancet 365 176-94
[9]
Kent DM(2001)The revised CONSORT statement for reporting randomized trials: explanation and elaboration Ann Intern Med 134 663-94
[10]
Hayward RA(2007)Statistics in medicine--reporting of subgroup analyses in clinical trials N Engl J Med 357 2189-9